CDK12 and prostate cancer: Moreover, as recently demonstrated in a subset of prostate cancers with CDK12 loss-of-function mutations53, the PCPA, as well as intron retention, observed with CDK12 inhibition could facilitate the formation of neoantigens that might be exploited to improve immune therapies or to develop personalized cancer vaccines54.